Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

VIMOVO

ESOMEPRAZOLE MAGNESIUM; NAPROXEN

Standard Dose
EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview VIMOVO is listed in Drugs@FDA under application 022511 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ESOMEPRAZOLE MAGNESIUM; NAPROXEN Form and strength TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HORIZON Submission history Latest submission status date: 2024-11-21 00:00:00.

Structured Monograph

Clinical summary

Approval overview VIMOVO is listed in Drugs@FDA under application 022511 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ESOMEPRAZOLE MAGNESIUM; NAPROXEN Form and strength TABLET, DELAYED RELEASE;ORAL - EQ 20MG BASE;375MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HORIZON Submission history Latest submission status date: 2024-11-21 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.